ZEVRA THERAPEUTICS, INC. Material Event Summary

Event Description

Zevra Therapeutics, Inc. has made two big, connected strategic moves. First, they sold their rights to the ADHD drug AZSTARYS® and all related intellectual property, including other serdexmethylphenidate (SDX)-based product candidates (we'll call this the "SDX portfolio"), to Commave Therapeutics SA. This sale, officially done through an Asset Purchase Agreement, brings Zevra $50 million in cash.

Second, Zevra used $38 million from the initial cash they got from this sale, plus $25 million from their own existing cash, to fully pay off their outstanding term loan. This loan, which was about $63 million (including the main amount, accumulated interest, and fees), was paid off much earlier than its original due date. This whole deal also settles all the ongoing legal disputes between Zevra and Commave Therapeutics SA that came from their earlier collaboration agreement for AZSTARYS®.

Event Date/Timeline

Zevra signed the Asset Purchase Agreement with Commave Therapeutics SA on March 12, 2024. The company then finished paying off its term loan on March 13, 2024. Zevra shared all these updates publicly through a press release on March 14, 2024.

Impact Assessment

• ZEVRA THERAPEUTICS, INC.: Zevra will now focus its strategy entirely on its rare disease pipeline. This means putting all their energy into key candidates like arimoclomol for Niemann-Pick disease Type C (NPC) and serdexmethylphenidate (SDX) for narcolepsy. This shift also gets rid of ongoing legal costs and the uncertainty that came with the Commave litigation. While the company is selling a product that was already on the market (AZSTARYS) and its related income, paying off the debt really strengthens their financial position, lowers financial risk, and frees up assets that were previously tied up as collateral.
• Commave Therapeutics SA: Commave now gets full control and commercialization rights over AZSTARYS and the entire SDX portfolio. With the legal issues with Zevra resolved, Commave has a clear path forward for developing and selling these products.
• Investors: Investors will see a significant strategic change for Zevra. This could lead to some ups and downs in the stock price as the market figures out the balance between a stronger financial sheet and a focused pipeline versus losing a product that was generating revenue.
• Customers/Patients: Getting AZSTARYS won't change immediately. However, Commave will now be the sole company guiding the drug's future development and sales.

Financial Impact

• Cash Inflow: Zevra will receive a total of $50 million in cash from Commave Therapeutics SA for selling the SDX portfolio. Zevra got an initial payment of $25 million, with the remaining $25 million coming in two parts: $12.5 million within 30 days of the deal closing and the final $12.5 million by December 31, 2024.
• Debt Repayment: The company completely paid off its outstanding term loan of about $63 million, which included the principal amount, accrued interest, and fees. Zevra used $38 million from the initial AZSTARYS sale proceeds and $25 million from its existing cash to make this payment.
• Reduced Debt and Interest Expense: Paying off the loan early removes approximately $63 million in long-term debt from their balance sheet. It also eliminates substantial future interest payments (which were estimated to be several million dollars annually) that would have continued until the loan's original maturity in 2029.
• Loss of Revenue Stream: Zevra will no longer get revenue or royalties from AZSTARYS sales, as they've sold all rights to the product. This means they're giving up a current revenue-generating asset.
• Liquidity and Financial Flexibility: This transaction significantly improves Zevra's cash position by reducing debt and bringing in cash. This gives them more financial freedom to invest in their main rare disease pipeline.

Key Takeaways for Investors

• Strategic Repositioning: Zevra is making a big strategic move, selling a commercial asset to become a company purely focused on rare diseases. Investors should now look at the potential of their remaining pipeline (arimoclomol for NPC, SDX for narcolepsy) as the main drivers of value.
• Strengthened Financial Position: The company's balance sheet is much less risky now, thanks to eliminating significant debt and future interest obligations. This gives them more financial flexibility for research and development and potential new strategic projects.
• Trade-off: Revenue vs. Focus: While the company gains financial strength and focus, it's giving up a current revenue stream from AZSTARYS. Investors need to weigh the long-term growth potential of the rare disease pipeline against the immediate loss of revenue from a commercial product.
• Potential for Volatility: A major corporate event like this can cause short-term ups and downs in the stock price as the market fully digests what the divestiture and debt repayment mean.
• Focus on Pipeline Milestones: Future investor attention will heavily concentrate on how their clinical trials are progressing, regulatory approvals, and potential commercialization efforts for Zevra's rare disease programs.